ArticleParasitology research2015
Potential application of nanochitosan film as a therapeutic agent against cutaneous leishmaniasis caused by L. major.
Article in Parasitology research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 28 citations in OpenAlex.
- The Designing of a Gel Formulation with Chitosan Polymer Using Liposomes as Nanocarriers of Amphotericin B for a Non-invasive Treatment Model of Cutaneous Leishmaniasis.Acta parasitologica · 2022Article
- Chitosan-based particulate systems for drug and vaccine delivery in the treatment and prevention of neglected tropical diseases.Drug delivery and translational research · 2020Review
- Chitosan Contribution to Therapeutic and Vaccinal Approaches for the Control of Leishmaniasis.Molecules (Basel, Switzerland) · 2020Review
- Activity of Chitosan and Its Derivatives against Leishmania major and Leishmania mexicanaAntimicrobial agents and chemotherapy · 2020Article
- Applications of Nanomaterials in Leishmaniasis: A Focus on Recent Advances and Challenges.Nanomaterials (Basel, Switzerland) · 2019Review
- Treatment of toxoplasmosis: Current options and future perspectives.Food and waterborne parasitology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antileishmanial drugs traditionally used for treatment of cutaneous leishmaniasis are mainly toxic, ineffective for some parasite isolates, and costly. Since chitosan is reported to accelerate wound healing, the aims of this study were to assess the effectiveness of nanochitosan films in the treatment of cutaneous leishmaniasis caused by Leishmania major (Iranian strain) and to investigate alterations of antioxidant enzyme activities and malondialdehyde levels. Six weeks after L. major inoculation, when lesions appeared at the base of the tail of 36 female Balb/c mice, treatment was initiated. Lesion sizes, parasite proliferation, histopathological changes, antioxidant enzyme activities, and malondialdehyde changes were evaluated in groups treated with nanochitosan film and groups treated with the combination of nanochitosan film and daily peritoneal injection of glucantime. There was no significant difference between nanochitosan and glucantime in reduction of lesion size. But, lesion sizes in the group that was treated with a combination of nanochitosan film and glucantime were significantly reduced from 2 weeks after treatment. The results of the present study showed that application of nanochitosan film increased the wound contraction rate, reepithelialization rate, and scar tissue formation, and its combination with glucantime significantly reduced lesion size and parasite loads. Nanochitosan films alone or in combination with glucantime enhanced glutathione peroxidase (GPX) activity and decreased lipid peroxidation and oxidative stress. The results of this work support the potential usefulness of nanochitosan as a therapeutic agent against cutaneous leishmaniasis caused by L. major.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.